Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Dermatology

Journal Scan / Research · June 12, 2023

Maintenance of Response to Bimekizumab Treatment Through 3 Years in Patients With Moderate to Severe Plaque Psoriasis

The British Journal of Dermatology


Additional Info

The British Journal of Dermatology
Bimekizumab maintenance of response through 3 years in patients with moderate-to-severe plaque psoriasis: results from the BE BRIGHT open-label extension trial
Br J Dermatol 2023 May 24;188(6)749-759, B Strober, Y Tada, U Mrowietz, M Lebwohl, P Foley, RG Langley, RB Warren, M Wang, V Vanvoorden, B Szilagyi, V Ciaravino, C Paul

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading